For Amylin Pharmaceuticals Inc., 1998 was a rough year. Poor results in a series of clinical trials caused the company to lay off 80 percent of its workers. By Oct. 22, the company’s shares had fallen from $6.62 to a low of 31 cents.
The shares began to climb, though, as the company figured out what had gone wrong in the clinical trials.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]